A Costly Truce: Bayer's Legal Settlement Sparks Stock Rebound

Bayer shares gain 4% after a $5.4B Roundup settlement gets preliminary approval, removing legal overhang despite a major cash flow hit. The firm also set new 2026 financial targets.

Investors in Bayer AG found a measure of relief this week as the company's shares halted a prolonged decline. The catalyst was a significant, albeit expensive, legal development in the United States concerning its Roundup weedkiller, coupled with the release of new financial targets for 2026. While the settlement provides much-needed clarity, its immediate financial impact is severe.

The key event was a preliminary approval granted by a judge in Missouri for a class-action settlement related to Roundup litigation. This legal milestone, however, comes with a staggering price tag. Bayer anticipates the settlement will cost approximately €5 billion this year, a figure that is expected to push its free cash flow deeply into negative territory, projected to be between -€1.5 billion and -€2.5 billion. Market participants appeared to prioritize the removal of uncertainty over the short-term financial pain, with the stock closing at €39.31 on Tuesday. This marked a weekly gain of nearly 4%, recovering from recent losses.

Operational Outlook and Annual Results

This legal news was accompanied by the company's final figures for the previous fiscal year. In the fourth quarter, Bayer reported a slight revenue decrease to €11.44 billion and posted a per-share loss of €3.68. Looking ahead, management expressed operational confidence for the current year. On a currency-adjusted basis, the company is targeting revenue in a range of €45 billion to €47 billion. Its core operating profit, measured as EBITDA before special items, is forecast to land between €9.6 billion and €10.1 billion.

Technical Perspective Points to Oversold Conditions

From a chart analysis standpoint, the recent upward move was not unexpected. The stock had recently been considered heavily oversold, with its 14-day Relative Strength Index (RSI) reading an extremely low 19.6. Despite the rebound, the shares remain down approximately 15% on a monthly view. The current price trades roughly 20% below its 52-week high of €49.17, which was reached in mid-February.

Analysts note that for the short-term downtrend to be decisively broken, the share price must first reclaim its 50-day moving average, situated at €42.83. The next major catalyst for fundamental direction is scheduled for May 12, 2026, when Bayer will present its results for the first quarter.